Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1991 1
1992 6
1993 3
1994 2
1995 6
1997 2
1998 4
1999 4
2000 1
2001 4
2002 4
2003 3
2004 6
2005 5
2006 2
2007 5
2008 7
2009 1
2010 3
2011 3
2012 5
2013 5
2014 3
2015 8
2016 4
2017 9
2018 9
2019 10
2020 12
2021 15
2022 5
2023 6
2024 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Results by year

Filters applied: . Clear all
Page 1
JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications.
Russell MD, Stovin C, Alveyn E, Adeyemi O, Chan CKD, Patel V, Adas MA, Atzeni F, Ng KKH, Rutherford AI, Norton S, Cope AP, Galloway JB. Russell MD, et al. Among authors: cope ap. Ann Rheum Dis. 2023 Aug;82(8):1059-1067. doi: 10.1136/ard-2023-224049. Epub 2023 May 29. Ann Rheum Dis. 2023. PMID: 37247942 Free PMC article.
EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors.
Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, Choy EH, Benesova K, Radstake TRDJ, Cope AP, Lambotte O, Gottenberg JE, Allenbach Y, Visser M, Rusthoven C, Thomasen L, Jamal S, Marabelle A, Larkin J, Haanen JBAG, Calabrese LH, Mariette X, Schaeverbeke T. Kostine M, et al. Among authors: cope ap. Ann Rheum Dis. 2021 Jan;80(1):36-48. doi: 10.1136/annrheumdis-2020-217139. Epub 2020 Apr 23. Ann Rheum Dis. 2021. PMID: 32327425 Free PMC article.
Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
Cope AP, Jasenecova M, Vasconcelos JC, Filer A, Raza K, Qureshi S, D'Agostino MA, McInnes IB, Isaacs JD, Pratt AG, Fisher BA, Buckley CD, Emery P, Ho P, Buch MH, Ciurtin C, van Schaardenburg D, Huizinga T, Toes R, Georgiou E, Kelly J, Murphy C, Prevost AT; APIPPRA study investigators. Cope AP, et al. Lancet. 2024 Mar 2;403(10429):838-849. doi: 10.1016/S0140-6736(23)02649-1. Epub 2024 Feb 13. Lancet. 2024. PMID: 38364839 Free article. Clinical Trial.
Emerging therapies for pre-RA.
Cope AP. Cope AP. Best Pract Res Clin Rheumatol. 2017 Feb;31(1):99-111. doi: 10.1016/j.berh.2017.08.005. Epub 2017 Sep 11. Best Pract Res Clin Rheumatol. 2017. PMID: 29221603 Review.
Rheumatoid arthritis prevention in arthralgia: fantasy or reality?
van Steenbergen HW, Cope AP, van der Helm-van Mil AHM. van Steenbergen HW, et al. Among authors: cope ap. Nat Rev Rheumatol. 2023 Dec;19(12):767-777. doi: 10.1038/s41584-023-01035-y. Epub 2023 Oct 9. Nat Rev Rheumatol. 2023. PMID: 37814057 Review.
Baricitinib set to join the Covid-19 therapeutic arsenal?
Gudu T, Stober C, Cope AP, Cheriyan J, Galloway J, Wilkinson IB, Kostapanos M, Jayne D, Hall F. Gudu T, et al. Among authors: cope ap. Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061. Rheumatology (Oxford). 2021. PMID: 33502499 Free PMC article. No abstract available.
Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
Hall FC, Cheriyan J, Cope AP, Galloway J, Wilkinson I, Bond S, Norton S, Banham-Hall E, Bayes H, Kostapanos M, Nodale M, Petchey WG, Sheeran T, Underwood J, Jayne DR; TACTIC-R Investigators Group. Hall FC, et al. Among authors: cope ap. Lancet Respir Med. 2023 Dec;11(12):1064-1074. doi: 10.1016/S2213-2600(23)00376-4. Epub 2023 Nov 14. Lancet Respir Med. 2023. PMID: 37977159 Free PMC article. Clinical Trial.
Planning your research training.
Cope AP, Brennan FM, Hill Gaston JS, Haskard DO. Cope AP, et al. Rheumatology (Oxford). 2005 Nov;44(11):1339-40. doi: 10.1093/rheumatology/kei098. Epub 2005 Sep 13. Rheumatology (Oxford). 2005. PMID: 16159949 No abstract available.
Therapeutic interception in individuals at risk of rheumatoid arthritis to prevent clinically impactful disease.
Deane KD, Holers VM, Emery P, Mankia K, El-Gabalawy H, Sparks JA, Costenbader KH, Schett G, van der Helm-van Mil A, van Schaardenburg D, Thomas R, Cope AP. Deane KD, et al. Among authors: cope ap. Ann Rheum Dis. 2024 Sep 24:ard-2023-224211. doi: 10.1136/ard-2023-224211. Online ahead of print. Ann Rheum Dis. 2024. PMID: 39242182 Free article. Review.
Interferon-α-mediated therapeutic resistance in early rheumatoid arthritis implicates epigenetic reprogramming.
Cooles FAH, Tarn J, Lendrem DW, Naamane N, Lin CM, Millar B, Maney NJ, Anderson AE, Thalayasingam N, Diboll J, Bondet V, Duffy D, Barnes MR, Smith GR, Ng S, Watson D, Henkin R, Cope AP, Reynard LN, Pratt AG; RA-MAP Consortium; Isaacs JD. Cooles FAH, et al. Among authors: cope ap. Ann Rheum Dis. 2022 Aug 11;81(9):1214-1223. doi: 10.1136/annrheumdis-2022-222370. Ann Rheum Dis. 2022. PMID: 35680389 Free PMC article.
160 results